[go: up one dir, main page]

BR9909626A - Compostos que inibem a ligação de integrina a seus receptores - Google Patents

Compostos que inibem a ligação de integrina a seus receptores

Info

Publication number
BR9909626A
BR9909626A BR9909626-9A BR9909626A BR9909626A BR 9909626 A BR9909626 A BR 9909626A BR 9909626 A BR9909626 A BR 9909626A BR 9909626 A BR9909626 A BR 9909626A
Authority
BR
Brazil
Prior art keywords
compounds
receptors
binding
integrin binding
inhibit
Prior art date
Application number
BR9909626-9A
Other languages
English (en)
Inventor
Ian L Scott
Raju G Bore
Ronald J Biediger
Vanessa O Grabbe
Jamal M Kassir
Karin M Keller
Shuqun Lin
Robert V Market
Timothy P Kogan
Original Assignee
Texas Biotechnology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Biotechnology Corp filed Critical Texas Biotechnology Corp
Publication of BR9909626A publication Critical patent/BR9909626A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

"COMPOSTOS QUE INIBEM A LIGAçãO DE INTEGRINA A SEUS RECEPTORES". Um processo para inibição da ligação de integrina <244>~ 4~<225>~ 1~ a seus receptores, por exemplo, VCAM-1 (molécula de adesão de célula vascular-1) e fibronectina; compostos que inibem esta ligação; composições farmaceuticamente ativas compreendendo tais compostos; e o uso de tais compostos tanto como acima, ou em formulações para o controle ou prevenção de estados de doença nos quais <244>~ 4~<225>~ 1~ está envolvida.
BR9909626-9A 1998-04-16 1999-04-15 Compostos que inibem a ligação de integrina a seus receptores BR9909626A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8201998P 1998-04-16 1998-04-16
PCT/US1999/008305 WO1999052493A2 (en) 1998-04-16 1999-04-15 Compounds that inhibit the binding of integrins to their receptors

Publications (1)

Publication Number Publication Date
BR9909626A true BR9909626A (pt) 2002-01-15

Family

ID=22168519

Family Applications (2)

Application Number Title Priority Date Filing Date
BR9909625-0A BR9909625A (pt) 1998-04-16 1999-04-15 Amidas n,n-di-substituìdas que inibem a ligação de integrinas a seus receptores
BR9909626-9A BR9909626A (pt) 1998-04-16 1999-04-15 Compostos que inibem a ligação de integrina a seus receptores

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR9909625-0A BR9909625A (pt) 1998-04-16 1999-04-15 Amidas n,n-di-substituìdas que inibem a ligação de integrinas a seus receptores

Country Status (20)

Country Link
US (3) US6096773A (pt)
EP (2) EP1079825B1 (pt)
JP (2) JP4949552B2 (pt)
KR (2) KR20010087125A (pt)
CN (2) CN1305473A (pt)
AT (2) ATE402170T1 (pt)
AU (2) AU3563799A (pt)
BR (2) BR9909625A (pt)
CA (2) CA2328234C (pt)
DE (2) DE69942610D1 (pt)
ES (2) ES2345471T3 (pt)
HU (2) HUP0103752A3 (pt)
ID (1) ID28658A (pt)
IL (2) IL138973A0 (pt)
NO (2) NO20005162L (pt)
NZ (1) NZ507534A (pt)
PL (2) PL343770A1 (pt)
SK (2) SK15592000A3 (pt)
TR (2) TR200100141T2 (pt)
WO (2) WO1999052493A2 (pt)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
BR9909625A (pt) 1998-04-16 2002-01-15 Texas Biotechnology Corp Amidas n,n-di-substituìdas que inibem a ligação de integrinas a seus receptores
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
EP1144384B1 (en) 1999-01-22 2007-10-31 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by vla-4
JP2002535304A (ja) 1999-01-22 2002-10-22 エラン ファーマシューティカルズ，インコーポレイテッド Ｖａｌ−４により媒介される白血球接着を阻害する多環式化合物
NZ512565A (en) 1999-01-22 2003-12-19 Elan Pharm Inc Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
AU3246600A (en) 1999-03-01 2000-09-21 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7 receptor antagonists
US6972296B2 (en) * 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
BR0016818A (pt) 1999-12-28 2002-10-01 Pfizer Prod Inc Inibidores não-peptidila de adesão celular dependente de vla-4 úteis no tratamento de doenças inflamatórias, auto-imunes e respiratórias
DE60141889D1 (de) 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
AU4875301A (en) * 2000-04-14 2001-10-30 Kureha Chemical Ind Co Ltd Nitrogenous compounds and antiviral drugs containing the same
ATE375330T1 (de) 2000-04-17 2007-10-15 Ucb Pharma Sa Enamin-derivate als zell-adhäsionsmoleküle
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&amp;D Limited 3-substituted isoquinolin-1-yl derivatives
DE10063173A1 (de) 2000-12-18 2002-06-20 Merck Patent Gmbh Harnstoff- und Urethanderivate
WO2002094261A1 (en) * 2001-05-24 2002-11-28 Kureha Chemical Industry Company, Limited Cxcr4-antagonistic drugs comprising nitrogen-containing compound
WO2002096424A1 (en) * 2001-05-25 2002-12-05 Queen's University At Kingston Hetereocyclic beta-aminoacids and their use as anti-epileptogenic agents
EP1431290A4 (en) * 2001-09-28 2004-12-15 Kureha Chemical Ind Co Ltd NITROGEN COMPOUND AND CORRESPONDING USE
SI21096B (sl) * 2001-10-09 2012-05-31 Encysive Pharmaceuticals Inc Derivati karboksilne kisline ki inhibirajo vezavo integrinov na njihove receptorje
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003265398A1 (en) * 2002-08-09 2004-02-25 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
KR100863667B1 (ko) 2002-09-11 2008-10-15 가부시끼가이샤 구레하 아민 화합물 및 그 용도
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
WO2005014532A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
CA2531796A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US8227434B1 (en) 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
CN1950343B (zh) * 2004-03-10 2013-06-19 株式会社吴羽 胺系碱性化合物及其用途
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
MX2008010988A (es) 2006-02-27 2008-10-20 Elan Pharm Inc Compuestos de pirimidinil sulfonamida que inhiben la adhesion de los leucocitos mediada por vla-4.
KR20110014199A (ko) 2008-05-13 2011-02-10 클라라산스, 인크. 비강 비염 치료용 재조합 인간 ｃｃ10 및 이의 조성물
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
NZ599511A (en) 2009-10-15 2014-06-27 Clarassance Inc Recombinant human cc10 protein for treatment of influenza
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
ES2677668T3 (es) * 2010-11-16 2018-08-06 Texas Heart Institute Agonistas que mejoran la unión de células que expresan integrina a receptores de integrina
WO2015136468A1 (en) 2014-03-13 2015-09-17 Prothena Biosciences Limited Combination treatment for multiple sclerosis
AU2015284263B2 (en) 2014-07-01 2021-02-25 7 Hills Pharma LLC Compositions and methods to improve adoptive cell therapies
US10875875B2 (en) * 2017-04-26 2020-12-29 Aviara Pharmaceuticals, Inc. Propionic acid derivatives and methods of use thereof
CA3114904A1 (en) * 2018-10-05 2020-04-09 Texas Heart Institute Imaging agents and methods of use
CN119462635A (zh) 2018-10-30 2025-02-18 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
KR20220047323A (ko) 2019-08-14 2022-04-15 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372974A (en) * 1980-06-25 1983-02-08 New York University Anticonvulsive compositions and method of treating convulsive disorders
US5654301A (en) * 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ZW6189A1 (en) * 1988-05-09 1990-05-09 Smithkline Beckman Corp Anti-aggregatory peptides
JPH0612525B2 (ja) 1989-10-12 1994-02-16 インターナショナル・ビシネス・マシーンズ・コーポレーション コンピュータプログラムの最適化方法
NZ235563A (en) * 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
NZ235564A (en) 1989-10-13 1993-10-26 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical compositions
US5192746A (en) * 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
JPH06192273A (ja) * 1992-10-26 1994-07-12 Lederle Japan Ltd カルバペネム−３−カルボン酸エステル誘導体
AU681396B2 (en) 1993-03-31 1997-08-28 G.D. Searle & Co. 1-amidinophenyl-pyrrolidones piperidinones azetinones as platelet aggregation inhibitors
JPH06298797A (ja) * 1993-04-12 1994-10-25 Fuji Photo Film Co Ltd ペプチド誘導体およびその用途
JP3190765B2 (ja) * 1993-05-13 2001-07-23 富士写真フイルム株式会社 ペプチド誘導体及びその用途
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5811391A (en) * 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
JP2920741B2 (ja) * 1994-12-14 1999-07-19 参天製薬株式会社 新規１，３−ジアルキルウレア誘導体
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL128221A (en) * 1996-07-25 2003-12-10 Biogen Inc Cell adhesion inhibitors
IL133638A0 (en) 1997-07-31 2001-04-30 Elan Pharm Inc 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
AU748041B2 (en) * 1997-10-31 2002-05-30 Aventis Pharma Limited Substituted anilides
GB9723789D0 (en) 1997-11-12 1998-01-07 Zeneca Ltd Chemical compounds
NZ504893A (en) * 1997-12-17 2002-10-25 Merck & Co Inc 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists
BR9909625A (pt) 1998-04-16 2002-01-15 Texas Biotechnology Corp Amidas n,n-di-substituìdas que inibem a ligação de integrinas a seus receptores

Also Published As

Publication number Publication date
EP1079825B1 (en) 2010-07-21
NZ507534A (en) 2002-02-01
CN1311676A (zh) 2001-09-05
ATE402170T1 (de) 2008-08-15
CA2328234C (en) 2009-03-17
JP4949552B2 (ja) 2012-06-13
JP4753403B2 (ja) 2011-08-24
HUP0101419A2 (hu) 2002-04-29
CA2328990A1 (en) 1999-10-21
KR20010042704A (ko) 2001-05-25
US6194448B1 (en) 2001-02-27
ATE474573T1 (de) 2010-08-15
HUP0103752A2 (hu) 2002-07-29
EP1071680B1 (en) 2008-07-23
CN1305473A (zh) 2001-07-25
NO20005161L (no) 2000-12-15
US6096773A (en) 2000-08-01
BR9909625A (pt) 2002-01-15
CA2328990C (en) 2011-01-11
AU3748399A (en) 1999-11-01
WO1999052493A2 (en) 1999-10-21
PL346220A1 (en) 2002-01-28
DE69939165D1 (de) 2008-09-04
NO20005162L (no) 2000-12-15
TR200100139T2 (tr) 2001-06-21
JP2002511463A (ja) 2002-04-16
TR200100141T2 (tr) 2001-06-21
CA2328234A1 (en) 1999-10-21
ES2308839T3 (es) 2008-12-01
IL138973A0 (en) 2001-11-25
US6262084B1 (en) 2001-07-17
IL138972A0 (en) 2001-11-25
HUP0101419A3 (en) 2002-08-28
ID28658A (id) 2001-06-21
SK15592000A3 (sk) 2001-12-03
EP1079825A2 (en) 2001-03-07
DE69942610D1 (de) 2010-09-02
WO1999052493A3 (en) 2000-12-28
EP1071680A1 (en) 2001-01-31
ES2345471T3 (es) 2010-09-23
PL343770A1 (en) 2001-09-10
EP1071680A4 (en) 2003-03-05
WO1999052898A1 (en) 1999-10-21
HUP0103752A3 (en) 2002-11-28
SK15602000A3 (sk) 2001-03-12
JP2002511397A (ja) 2002-04-16
KR20010087125A (ko) 2001-09-15
NO20005162D0 (no) 2000-10-13
AU3563799A (en) 1999-11-01
EP1079825A4 (en) 2003-03-05
NO20005161D0 (no) 2000-10-13

Similar Documents

Publication Publication Date Title
BR9909626A (pt) Compostos que inibem a ligação de integrina a seus receptores
BR0010349C1 (pt) Derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores
DK1176956T3 (da) Carboxylsyrederivater, som inhiberer bindingen af integriner til deres receptorer
BR9707958A (pt) Composto, composição farmacêutica, e, processo para tratar hiperalgesia em um paciente.
BR9810712A (pt) Processo para a prevenção ou tratamento de prurido em um paciente
HK1048469A1 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors
NO20015394L (no) Karboksylsyrederivater som hemmer bindingen av integriner til deres reseptorer
BR0316104A (pt) Produtos de combinação com derivados ácido carboxìlico que inibem a ligação de integrins aos seus receptores e outros compostos terapêuticos
GT199700054A (es) Pesticidas que contienen alcaloides de benzofenantridina
BR0010293A (pt) Derivados de ácido carboxìlico que inibem a ligação de integrinas para seus receptores
BR9915835A (pt) Composição farmacêutica, e, processo para a preparação de uma composição
BR0106840A (pt) Derivados de ácido carboxìlico que inibem a ligação de integrinas aos seus receptores

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O,5O, 6O, 7O E 8O ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.